Key TakeawaysDHR shares have declined approximately 11% over the past week and are down 21% year-to-date, currently trading at $179.01Second quarter adjusted earnings per share of $1.94 exceeded analyst expectations of $1.83; revenue of $6.3B surpassed the $6.1B consensusThe bioprocessing division underperformed significantly, delivering only low single-digit growth figuresMajor Wall Street firms including Guggenheim, Stifel, and BofA reduced their price targets while maintaining Buy recommendationsA total of 10 analysts have lowered their earnings projections for the coming periodDespite delivering quarterly results that exceeded Wall Street’s expectations, Danaher’s stock performance tells a troubling story. Shares plummeted approximately 11% throughout the week to reach $179.01, as market participants focused intently on disappointing bioprocessing performance rather than celebrating the company’s headline achievements.Danaher Corporation, DHRThe company’s adjusted earnings per share reached $1.94, comfortably exceeding the Wall Street consensus of $1.83. Total revenue hit $6.3 billion, surpassing analyst forecasts of $6.1 billion. At first glance, these figures suggest a successful quarter.However, the bioprocessing division painted a considerably different picture. This segment delivered only low single-digit growth figures — significantly missing market expectations — with company management pointing to timing issues related to particular products and customer relationships as the primary culprits.The market appears skeptical of this rationale. Concerns regarding potential market share erosion have emerged, and Wall Street analysts have highlighted insufficient transparency surrounding the miss.BofA analyst Michael Ryskin characterized the quarterly performance as “certainly messier than expected,” citing the bioprocessing disappointment as the primary driver. While maintaining his Buy recommendation, he slashed his price objective from $270 down to $230.Ryskin emphasized that this represents “not the first setback or headwind to pop up in recent years” for the company, suggesting Danaher now faces the challenge of restoring investor confidence in both its fundamental business model and management’s ability to execute.Wall Street Firms Slash Price ObjectivesGuggenheim reduced its price target from $235 down to $200 while preserving its Buy rating. The investment firm highlighted persistent uncertainty within the bioprocessing segment and predicted similar concerns would emerge during peer company earnings announcements throughout the week.Stifel adjusted its target downward from $260 to $220, also maintaining a Buy stance. The firm emphasized expectations for continued weakness in the third quarter and calculated that fourth quarter growth would need to reach mid-single digit levels simply to achieve the lower bound of the company’s full-year 3% growth guidance.Despite the price target reductions, all three major firms retained their Buy recommendations. According to InvestingPro data, the stock appears undervalued at present trading levels even after the recent selloff.The Path ForwardDanaher continues to forecast high single-digit growth potential for its bioprocessing operations. However, achieving this target requires strong fourth quarter execution, and current investor sentiment remains decidedly negative.According to Stifel, the near-term trajectory hinges significantly on how earnings season unfolds across the broader Tools sector. Should sector-wide confidence remain stable, DHR could stage a recovery. However, if sentiment deteriorates further, Stifel anticipates Danaher will likely underperform relative to peers.A total of ten analysts have now reduced their earnings forecasts for the upcoming reporting period.As of July 22, 2026, Danaher stock has declined 21% on a year-to-date basis.The post Danaher (DHR) Stock Tumbles 11% as Bioprocessing Struggles Overshadow Earnings Beat appeared first on Blockonomi.